Search Result

Isoforms Recommended:	ERα

Results for "

ER-α

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (13) Autophagy (1) Bacterial (1) Cytochrome P450 (3) Deubiquitinase (2) Drug Metabolite (1) Endogenous Metabolite (1) Estrogen Receptor/ERR (98) FATP (1) Histone Demethylase (1) Isotope-Labeled Compounds (5) Ligands for E3 Ligase (1) Ligands for Target Protein for PROTAC (1) Microtubule/Tubulin (1) NF-κB (1) Potassium Channel (2) Prostaglandin Receptor (1) PROTAC-Linker Conjugates for PAC (1) PROTACs (11) Reactive Oxygen Species (1) RET (1) Smo (1) SNIPERs (2) Wnt (1)
By Research Areas:	Cancer (99) Cardiovascular Disease (2) Endocrinology (10) Infection (2) Inflammation/Immunology (3) Metabolic Disease (4) Neurological Disease (3)

By Targets:

Apoptosis (13)

Autophagy (1)

Bacterial (1)

Cytochrome P450 (3)

Deubiquitinase (2)

Drug Metabolite (1)

Endogenous Metabolite (1)

Estrogen Receptor/ERR (98)

FATP (1)

Histone Demethylase (1)

Isotope-Labeled Compounds (5)

Ligands for E3 Ligase (1)

Ligands for Target Protein for PROTAC (1)

Microtubule/Tubulin (1)

NF-κB (1)

Potassium Channel (2)

Prostaglandin Receptor (1)

PROTAC-Linker Conjugates for PAC (1)

PROTACs (11)

Reactive Oxygen Species (1)

RET (1)

Smo (1)

SNIPERs (2)

Wnt (1)

By Research Areas:

Cancer (99)

Cardiovascular Disease (2)

Endocrinology (10)

Infection (2)

Inflammation/Immunology (3)

Metabolic Disease (4)

Neurological Disease (3)

112

Inhibitors & Agonists

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-132194

ERα degrader-2	Estrogen Receptor/ERR	Cancer
ERα degrader-2 is a selective estrogen receptor degrader (SERD) with potent binding affinity with *ERα* (IC₅₀=17.1 nM), good degradation efficacy (EC₅₀=0.3 nM). ERα degrader-2 exhibits favorable pharmacokinetic properties and excellent agentgability, can be used for HER ⁺ breast cancer research .

HY-168099

ERα degrader 10	Estrogen Receptor/ERR	Cancer
ERα degrader 10 is a selective and orally active estrogen receptor α (ERα) degrader. ERα degrader 10 exhibits potent ERα binding affinity (IC₅₀ of 24.0 nM) and degradation ability (EC₅₀ of 5.3 nM). ERα degrader 10 degrades ERα through the proteasome-mediated pathway. ERα degrader 10 can be used for the study of breast cancer .

HY-163680

ERα degrader 9	Estrogen Receptor/ERR Cytochrome P450	Cancer
ERα degrader 9 is a dual targeting ligand for estrogen receptor α (ERα) and aromatase (ARO). ERα degrader 9 can be utilized for synthesis of PROTAC ERα Degrader-9 (HY-163679) .

HY-149081

ERα degrader 6	Estrogen Receptor/ERR Cytochrome P450	Cancer
ERα degrader 6 (Compound 31q) is an *ERα* degrader (K_I: 75 nM). ERα degrader 6 also inhibits ARO with an IC₅₀ of 37.7 nM. ERα degrader 6 inhibits tumor growth in MCF-7 tumor xenograft model. ERα degrader 6 can be used for breast cancer research .

HY-146267

ERα degrader 5	Estrogen Receptor/ERR	Cancer
ERα degrader 5 (Compound 40) is a selective, orally bioavailable estrogen receptor (ER) degrader (SERD) with an EC₅₀ of 1.1 nM against *ERα. ERα* degrader 5 shows antitumor effect in vivo .

HY-144733

ERα antagonist 1	Estrogen Receptor/ERR Apoptosis	Cancer
ERα antagonist 1 (Compound 19d) is a potent, selective, covalent estrogen receptor α (ERα) antagonist. ERα antagonist 1 induces apoptosis and cell cycle G0/G1 phase arrest in MCF-7 cells .

HY-144306

ERα degrader 4	Estrogen Receptor/ERR Apoptosis	Cancer
ERα degrader 4 is an excellent and selective estrogen receptor α (ERα) degrader (IC₅₀ of 0.31, 0.41 and 0.48 μM in MDA-MB-231, MCF-7 and MCF-7/ADR cells, respectively). ERα degrader 4 has potent inhibitory activity against MCF-7 cell lines. ERα degrader 4 is a potential SERDs candidate for the research of breast cancer .

HY-155492

ERα degrader 7	Estrogen Receptor/ERR	Cancer
ERα degrader 7 (compound B1) is a potent *ERα* degrader with an IC₅₀ of 14.6 nM and a DC₅₀ of 9.7 nM, respectively. ERα degrader 7 shows excellent antitumor activity, indicating its potential to evolve as a promising selective estrogen-receptor degrader (SERD) for breast cancer research .

HY-168101

ERα degrader 11	Estrogen Receptor/ERR	Cancer
ERα degrader 11 (compound B16) is a selective *ERα* degrader that can be used as an estrogen receptor probe to investigate ER status in ER-positive breast cancer cells .

HY-161692

ERα degrader 8	Estrogen Receptor/ERR	Cancer
ERα degrader 8 (Compound 18j) is a selective Estrogen Receptor degrader. ERα degrader 8 is degrader to MCF-7 cells with IC₅₀ value of 0.15 μM .

HY-111845

Estrone-N-O-C1-amido ERα ligand 1	Estrogen Receptor/ERR Ligands for Target Protein for PROTAC	Cancer
Estrone-N-O-C1-amido (ERα ligand 1) is an Estrone-based estrogen ligand, which targets estrogen receptor α (ERα). Estrone-N-O-C1-amido (ERα ligand 1) binds to cIAP1 ligand Bestatin via a linker to form SNIPER .

HY-P10393

ERα17p ERα (295-311)	Apoptosis	Cancer
ERα17p (ERα 295-311) is the epitope of the CaM binding site on the estrogen receptor α (ER), which interacts with calmodulin (CaM) in a calcium-dependent manner. ERα17p regulates the migration of cancer cells MCF-7, SK-BR-3, T47D, and MDA-MB-231 through Rho/ROCK and PI3K/Akt signaling pathways. ERα17p inhibits proliferations of breast cancer cells, induces apoptosis, and inhibits tumor growth in mouse models .

HY-N7748A

Epi-cryptoacetalide	Estrogen Receptor/ERR Prostaglandin Receptor	Inflammation/Immunology Endocrinology
Epi-cryptoacetalide is a natural diterpenoid. Epi-cryptoacetalide reveals high affinity to *ER-α* and PGE2 receptor (EP2 subtype) with K_i values of 0.3 μM and 1.92 μM, respectively. Epi-cryptoacetalide has anti-endometriosis activities .

HY-163467

CHEMBL4224880	Others	Cancer
CHEMBL4224880 is an estrogen receptor-α (ER-α) binder .

HY-157765

*PROTAC ERα* Degrader-6**	PROTACs Estrogen Receptor/ERR	Cancer
PROTAC ERα Degrader-6 (compound A3) is a potent PROTAC degrader of *ERα, with DC₅₀* of 0.12 μM. PROTAC ERα Degrader-6 has anti-tumor effect. PROTAC ERα Degrader-6 is a fluorescent probes with Em of 582 nm that enable real-time visualization of ERα protein degradation .

HY-149295

*PROTAC ERα* Degrader-4**	PROTACs Estrogen Receptor/ERR Apoptosis	Cancer
PROTAC ERα Degrader-4 is a highly potent and selectivePROTAC *ERα* degrader (K_i: 5.08 μM). PROTAC ERα Degrader-4 contains OBHSAs, linker and E3 ligase ligands. PROTAC ERα Degrader-4 shows excellent cell inhibitory and ERα degradation activity against Tamoxifen-sensitive and -resistant ER ⁺ breast cancer (BC) cells and ERα-mutated BC cells. PROTAC ERα Degrader-4 can induce apoptosis and can be used for cancer research.

HY-111846

*PROTAC ERα* Degrader-2**	SNIPERs PROTACs Estrogen Receptor/ERR	Cancer
PROTAC ERα Degrader-2 comprises a IAP ligand binding group, a linker and an estrogen receptor α (ERα) binding group. PROTAC ERα Degrader-2 is an *ERα* degrader. Maximal ERα degradation at 30 μM concentration in human mammary tumor MCF7 cells. Degradation inducers based on cIAP1 are called specific and non-genetic IAP-dependent protein erasers (SNIPERs) .

HY-112098

*PROTAC ERα* Degrader-1**	PROTACs Estrogen Receptor/ERR	Cancer
PROTAC ERα Degrader-1 comprises an ubiquitin E3 ligase binding group, a linker and a protein binding group. PROTAC ERα Degrader-1 extracts from patent WO2017201449A1, compound P1. PROTAC ERα Degrader-1 is an estrogen receptor-alpha (ERα) degrader.

HY-160562

*PROTAC ERα* Degrader-7**	PROTACs Estrogen Receptor/ERR	Cancer
PROTAC ERα Degrader-7 (compound i-320) is a potent estrogen receptor alpha(ERα) PROTAC degrader with a DC₅₀ value of 0.000006 µM. PROTAC ERα Degrader-7 comprises a cereblon-binding moiety LBM linked to a ligand ERBM that binds ERα and comprises a benzofused partially saturated 6-membered carbocyclic or heterocyclic ring .

HY-112100

*PROTAC ERα* Degrader-5**	PROTAC-Linker Conjugates for PAC Estrogen Receptor/ERR	Cancer
PROTAC ERα Degrader-5 (compound LP2) consists an ADC linker and a PROTAC, whcih can be conjugated to an antibody to form PACs. PROTAC ERα Degrader-5 conjugated to an antibody is a more marked estrogen receptor-alpha (ERα) degrader compared to PROTAC (without Ab) .

HY-160563

*PROTAC ERα* Degrader-8**	PROTACs Estrogen Receptor/ERR	Cancer
PROTAC ERα Degrader-8 (compound ii-56) is a potent PROTAC degrader of *Erα, with DC₅₀* of 0.000006 μM in MCF7 cells .

HY-145556

Bexirestrant	Estrogen Receptor/ERR	Cancer
Bexirestrant is an orally active *ER-α* degrader. Bexirestrant can be used for the research of antiestrogen, antineoplastic .

HY-163679

*PROTAC ERα* Degrader-9**	Estrogen Receptor/ERR Cytochrome P450 PROTACs Apoptosis	Cancer
PROTAC ERα Degrader-9 (Compound 18c) is a dual-targeting PROTAC degrader, which degrades estrogen receptor α (ERα) and aromatase (ARO). PROTAC ERα Degrader-9 binds to ERα with a K_i of 0.25 μM, inhibits ARO with an IC₅₀ of 4.6 μM. PROTAC ERα Degrader-9 inhibits the proliferation of MCF-7 wildtype (IC₅₀=0.54 μM) and ERα mutants MCF-7 ^EGFR (IC₅₀=0.075 μM), MCF-7 ^D538G (IC₅₀=0.31 μM), MCF-7 ^Y537S (IC₅₀=2.3 μM), downregulates the expressions of ERS1 and MYC. PROTAC ERα Degrader-9 arrests the cell cycle at G2/M, induces apoptosis in MCF-7. PROTAC ERα Degrader-9 exhibits antitumor efficacy in mouse models. (Pink: ligand for target protein (HY-163680); Black: linker (HY-W007559); Blue: ligand for E3 ligase (HY-112078))

HY-156125

*14-3-3σ/ERα* stabilizer-1**	Estrogen Receptor/ERR	Others
14-3-3σ/ERα stabilizer-1 (Compound 181) is a covalent *14-3-3σ/ERα* stabilizer. 14-3-3σ/ERα stabilizer-1 can be used for research of molecular glues .

HY-145071

*PROTAC ERα* Y537S degrader-1**	PROTACs Estrogen Receptor/ERR	Cancer
PROTAC ERα Y537S degrader-1 comprises a ubiquitin E3 ligase binding group, a linker and a protein binding group. PROTAC ERα Y537S degrader-1 extracts from patent WO2021143822, example 12. PROTAC ERα Y537S degrader-1 is an estrogen receptor-alpha (ERα) Y537S degrader .

HY-111484A

GDC-0927 Racemate SRN-927 Racemate	Estrogen Receptor/ERR	Cancer
GDC-0927 Racemate (SRN-927 Racemate) is a degrader of estrogen receptor, potently inhibits *ER-α* activity, with an IC₅₀ of 0.2 nM, and is used in the research of ER-related diseases.

HY-19498

WAY-204688 SIM-688	NF-κB	Inflammation/Immunology
WAY-204688 is an estrogen receptor (ER-α) selective, orally active inhibitor of NF-κB transcriptional activity with an IC₅₀ of 122 ± 30 nM for NF-κB-luciferase (NF-κB-luc) in HAECT-1 cells.

HY-155196

ER degrader 6	Estrogen Receptor/ERR	Cancer
ER degrader 6 (compound 35s) is a potent Estrogen Receptor (ER)α degrader. ER degrader 6 disrupts the microtubule network by restraining tubulin polymerization. ER degrader 6 suppresses tumor growth without noticeable poisonousness .

HY-137144

Fulvestrant-3-boronic acid ZB716	Estrogen Receptor/ERR	Cancer
Fulvestrant-3-boronic acid is an orally active *ERα* inhibitor, which binds to ERα competitively (IC₅₀ = 4.1 nM) and effectively degrades ERα in breast cancer cells .

HY-100689

Propyl pyrazole triol 10+ Cited Publications PPT	Estrogen Receptor/ERR	Cancer
Propyl pyrazole triol (PPT) is a selective estrogen receptor alpha (ERα) agonist. The relative binding affinity of Propyl pyrazole triol for ERα (ERα: 49%) around 410 times higher compared with estrogen receptor beta (ERβ: 0.12%) .

HY-103451

(R,R)-THC	Estrogen Receptor/ERR	Metabolic Disease
(R,R)-THC is an ERα agonist and an ERβ antagonist, with K_is of 9.0 nM and 3.6 nM for ERα and ERβ, respectively. (R,R)-THC has higher relative binding affinity for ERβ than ERα with the values of 25 and 3.6 .

HY-112611

H3B-5942	Estrogen Receptor/ERR	Cancer
H3B-5942 is a selective, irreversible and orally active estrogen receptor covalent antagonist, inactivates both wild-type and mutant *ERα* by targeting Cys530, with K_is of 1 nM and 0.41 nM, respectively. H3B-5942 reduces ERα target gene GREB1, shows potent antitumor activity both in multiple cell lines or animals bearing ERα ^WT or ERα mutations .

HY-129619

SNIPER(ER)-87	SNIPERs Estrogen Receptor/ERR	Cancer
SNIPER(ER)-87 consists of an inhibitor of apoptosis protein (IAP) ligand LCL161 derivative that is conjugated to the estrogen receptor α (ERα) ligand 4-hydroxytamoxifen by a PEG linker, and efficiently degrades the *ERα* protein (IC₅₀=0.097 μM). SNIPER(ER)-87 preferentially recruits XIAP to ERα in the cells, and XIAP is the primary E3 ubiquitin ligase responsible for the SNIPER(ER)-87-induced ERα degradation .

HY-144070A

(Rac)-ErSO-DFP	Estrogen Receptor/ERR	Cancer
(Rac)-ErSO-DFP is a derivative of ErSO-DFP and a selective small molecule *Erα* biomodulator. (Rac)-ErSO-DFP againsts *ERα+* breast cancer (including resistant tumors) by hyperactiving the Erα-dependent a-UPR (extracted from patent WO2022087234A1) .

HY-131404

TPBM	Estrogen Receptor/ERR	Cancer
TPBM is a potent estrogen receptor α (ERα) inhibitor with an IC₅₀ value of 9 μM for 17β-estradiol (E2)-ERα. TPBM reduces E2·ERα recruitment to an endogenous estrogen-responsive gene. TPBM inhibits E2-dependent growth of ERα-positive cancer cells (IC₅₀=5 μM). TPBM is not toxic to cells and does not affect estrogen-independent cell growth .

HY-108414

(R)-Equol (+)-Equol	Estrogen Receptor/ERR	Cancer
(R)-Equol is an agonist of both *ERα* and ERβ with K_is of 27.4 and 15.4 nM, respectively.

HY-132294A

(1S,3R)-GNE-502	Estrogen Receptor/ERR	Cancer
(1S,3R)-GNE-502 (compound 179) is a potent *ERα* degrader with an EC₅₀ value of 13 nM against ERα in MCF7 HCS. (1S,3R)-GNE-502 can be used to research cancer related with estrogen receptor .

HY-146424

OBHS	Estrogen Receptor/ERR	Neurological Disease Cancer
OBHS is an *estrogen receptor α (ERα) inhibitor*. OBHS can also be used as a blowing agent .

HY-103456

PHTPP 20+ Cited Publications	Estrogen Receptor/ERR	Cancer
PHTPP is a selective estrogen receptor β (ERβ) antagonist with 36-fold selectivity over ERα .

HY-N2448

Lindleyin	Estrogen Receptor/ERR	Endocrinology
Lindleyin, isolated from Rhei rhizoma, mediates hormonal effects through estrogen receptors. Lindleyin binds to *ERα* with estrogenic activity .

HY-103453

(R)-DPN	Estrogen Receptor/ERR	Endocrinology
(R)-DPN (compound 3) is a selective ERβ ligand with EC₅₀s of 2.9, 0.8 nM for ERα and ERβ, respectively. (R)-DPN shows a very high affinity and potency preference for ERβ over ERα. (R)-DPN shows cytoxicity for HEC-1 and U2OS cells with EC₅₀s of 286, 205 nM, respectively .

HY-119418

Desketoraloxifene	Estrogen Receptor/ERR	Cancer
Desketoraloxifene is an estrogen receptors alpha (ERα) activator at an AP-1 site. Desketoraloxifene can be used for the research of osteoporosis and breast cancer .

HY-103457

Y134	Estrogen Receptor/ERR	Cancer
Y134 is a selective and orally active oestrogen receptor (ER) modulator (SERM), exhibits potent antagonist activity at *ERα* and ERβ. Y134 shows 121.1-fold selectivity for ERα (K_i=0.09 nM) over ERβ (K_i=11.31 nM). Y134 inhibits oestrogen-stimulated proliferation of ER-positive human breast cancer cells .

HY-150803

VHL Ligand 14	Ligands for E3 Ligase	Cancer
VHL Ligand 14 (Compound 11) is a VHL ligand for design of PROTAC estrogen receptor α (ERα) degraders, with a binding affinity IC₅₀ of 196 nM .

HY-12870

AZD9496 Maximum Cited Publications 25 Publications Verification	Estrogen Receptor/ERR	Cancer
AZD9496 is a potent and selective estrogen receptor (ERα) antagonist with an IC₅₀ of 0.28 nM. AZD9496 is an orally bioavailable selective oestrogen receptor degrader (SERD).

HY-12870A

AZD9496 maleate Maximum Cited Publications 25 Publications Verification	Estrogen Receptor/ERR	Cancer
AZD9496 maleate is a potent and selective estrogen receptor (ERα) antagonist with IC₅₀ of 0.28 nM. AZD9496 maleate is an orally bioavailable selective oestrogen receptor degrader (SERD).

HY-100583A

(±)-Equol	Estrogen Receptor/ERR Drug Metabolite	Cardiovascular Disease Neurological Disease Cancer
(±)-Equol is the racemate of equol. (±)-equol exhibits EC₅₀s of 200 and 74 nM for human ERα and ERβ, respectively. Equol is a metabolite of the soy isoflavones, daidzin and daidzein.

HY-18719A

Endoxifen Z-isomer hydrochloride 3 Publications Verification	Estrogen Receptor/ERR Potassium Channel	Cancer
Endoxifen Z-isomer hydrochloride is the most important Tamoxifen metabolite responsible for eliciting the anti-estrogenic effects of this drug in breast cancer cells expressing estrogen receptor-alpha (ERα).

HY-N0233

Bavachin 5+ Cited Publications Corylifolin	Estrogen Receptor/ERR	Cancer
Bavachin, a flavonoid first isolated from seeds of P. corylifolia, acts as a phytoestrogen that activates the estrogen receptors ERα and ERβ with EC₅₀s of 320 and 680 nM, respectively.

HY-150601

Estrogen receptor-IN-1	Estrogen Receptor/ERR	Metabolic Disease
Estrogen receptor-IN-1 (compound 16) is a potent estrogen receptor (ER) inhibitor with IC₅₀s of 13, 5µM for ERα and Erβ, respectively .

Cat. No.	Product Name	Target	Research Area

HY-P10393

ERα17p ERα (295-311)	Apoptosis	Cancer
ERα17p (ERα 295-311) is the epitope of the CaM binding site on the estrogen receptor α (ER), which interacts with calmodulin (CaM) in a calcium-dependent manner. ERα17p regulates the migration of cancer cells MCF-7, SK-BR-3, T47D, and MDA-MB-231 through Rho/ROCK and PI3K/Akt signaling pathways. ERα17p inhibits proliferations of breast cancer cells, induces apoptosis, and inhibits tumor growth in mouse models .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2448

Lindleyin	Classification of Application Fields Rheum palmatum L. Polygonaceae Source classification Phenols Polyphenols Plants Disease Research Fields Endocrinology	Estrogen Receptor/ERR
Lindleyin, isolated from Rhei rhizoma, mediates hormonal effects through estrogen receptors. Lindleyin binds to *ERα* with estrogenic activity .

HY-100583A

(±)-Equol	Cardiovascular Disease Structural Classification Monophenols Neurological Disease Classification of Application Fields Leguminosae Glycine max (L.) merr Source classification Phenols Polyphenols Plants Disease Research Fields	Estrogen Receptor/ERR Drug Metabolite
(±)-Equol is the racemate of equol. (±)-equol exhibits EC₅₀s of 200 and 74 nM for human ERα and ERβ, respectively. Equol is a metabolite of the soy isoflavones, daidzin and daidzein.

HY-N0233

Bavachin Maximum Cited Publications 6 Publications Verification Corylifolin	Structural Classification Flavonoids Classification of Application Fields Leguminosae Flavonones Source classification Phenols Polyphenols Psoralea corylifolia L. Plants Disease Research Fields Cancer	Estrogen Receptor/ERR
Bavachin, a flavonoid first isolated from seeds of P. corylifolia, acts as a phytoestrogen that activates the estrogen receptors ERα and ERβ with EC₅₀s of 320 and 680 nM, respectively.

HY-N4121

Isocurcumenol 1 Publications Verification	Structural Classification other families Classification of Application Fields Terpenoids Sesquiterpenes Source classification Plants Disease Research Fields Cancer	Estrogen Receptor/ERR Apoptosis
Isocurcumenol, an estrogen receptor alpha (ERα) inhibitor isolated from Curcuma zedoaria Rhizomes, possesses anti-tumor acticity, with IC₅₀ values of 99.1μg/mL and 178.2 μg/mL in DLA and KB cells, respectively .

HY-B0412

Estriol 3 Publications Verification Oestriol	Structural Classification Monophenols Immune System Disorder Classification of Application Fields Source classification Disease markers Phenols Endocrine diseases Endogenous metabolite Disease Research Fields Steroids Cancer	Estrogen Receptor/ERR Endogenous Metabolite
Estriol (Oestriol), an orally active estrogen, is a *ERα* and ERβ agonist. Estriol is a potent GPR30 antagonist in estrogen receptor-negative breast cancer cells. Estriol can ameliorate disease severity through immunomodulatory mechanisms that decrease tissue inflammation. Estriol has powerful proconvulsant effects .

HY-125703

Ferutinin	Viguiera dentata (Cav.) Spreng. Infection Structural Classification Classification of Application Fields Terpenoids Sesquiterpenes Source classification Umbelliferae Plants Disease Research Fields Endocrinology Cancer	Estrogen Receptor/ERR Apoptosis
Ferutinin, a natural terpenoid compound, is an estrogen receptor ERα agonist and estrogen ERβ-receptor agonist/antagonist with IC₅₀s of 33.1 nM and 180.5 nM, respectively. Ferutinin acts as an electrogenic Ca ²⁺-ionophore that increases calcium permeability of lipid bilayer membranes, mitochondria. Ferutinin possesses estrogenic, antitumor, antibacterial and antiinflammatory activities .

HY-N0401A

(Z)-Ligustilide 3 Publications Verification	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Dicerothamnus rhinocerotis Umbelliferae Plants Disease Research Fields	Bacterial Estrogen Receptor/ERR FATP
(Z)-Ligustilide is extracted from Ligusticum chuanxiong Hort, has antimicrobial and antifungal activity, exhibits an average antifungal score of 5.6 . (Z)-Ligustilide is orally active, it inhibits the expression of FATP5 and DGAT, inhibits fatty acid uptake and esterification in mice and has potential as therapeutics for nonalcoholic fatty liver disease (NAFLD) . (Z)-Ligustilide is also able to reactivate ERα, has epigenetic regulation, and is used in the study of tamoxifen-resistant breast cancer .

HY-122815

Fusicoccin Fusicoccin A	Microorganisms Classification of Application Fields Terpenoids Source classification Diterpenoids Disease Research Fields Cancer	Apoptosis
Fusicoccin (Fusicoccin A), a fungal pytotoxin, is a stabilizer of specific 14-3-3 protein-protein interactions. Fusicoccin sabilizes H ⁺-ATPase/14-3-3 cmplex in pants, maintaining the enzyme in activated state. Fusicoccin also stabilizes 14-3-3 protein interactions with binding partners containing a C-terminal 14-3-3 recognition motif (a mode 3 motif), such as ERα, GPIbα, TASK3, CTFR, and p53. Fusicoccin induces apoptosis in cancer cells and has anticancer activity .

HY-N7748A

Epi-cryptoacetalide	Terpenoids Labiatae Samanea saman (Jacq.) Merr. Diterpenoids Plants	Estrogen Receptor/ERR Prostaglandin Receptor
Epi-cryptoacetalide is a natural diterpenoid. Epi-cryptoacetalide reveals high affinity to *ER-α* and PGE2 receptor (EP2 subtype) with K_i values of 0.3 μM and 1.92 μM, respectively. Epi-cryptoacetalide has anti-endometriosis activities .

HY-N0233R

Bavachin (Standard)	Structural Classification Flavonoids Leguminosae Flavonones Source classification Phenols Polyphenols Psoralea corylifolia L. Plants	Estrogen Receptor/ERR
Bavachin (Standard) is the analytical standard of Bavachin. This product is intended for research and analytical applications. Bavachin, a flavonoid first isolated from seeds of P. corylifolia, acts as a phytoestrogen that activates the estrogen receptors ERα and ERβ with EC50s of 320 and 680 nM, respectively.

Species:	Human (2)
Tag:	His (2)
Source:	P. pastoris (1) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P70248

	ER alpha/ESR1 Protein, Human (His) 1 Publications Verification rHuEstrogen receptor/ER alpha, His; Estrogen Receptor; ER; ER-Alpha; Estradiol Receptor; Nuclear Receptor Subfamily 3 Group A MembER 1; ESR1; ESR; NR3A1	Human	E. coli
	The ER α/ESR1 protein is a nuclear receptor that plays a critical regulatory role in gene expression, affecting cell proliferation and differentiation. Ligand-dependent transactivation involves binding of homodimers to estrogen response elements or association with transcription factors. ER alpha/ESR1 Protein, Human (His) is the recombinant human-derived ER alpha/ESR1 protein, expressed by E. coli , with N-6*His labeled tag.

HY-P701106

	ER alpha/ESR1 Protein, Human (P. pastoris, N-His) rHuEstrogen receptor/ER alpha, His; Estrogen Receptor; ER; ER-Alpha; Estradiol Receptor; Nuclear Receptor Subfamily 3 Group A MembER 1; ESR1; ESR; NR3A1	Human	P. pastoris
	The ER α/ESR1 protein is a nuclear receptor that plays a critical regulatory role in gene expression, affecting cell proliferation and differentiation. Ligand-dependent transactivation involves binding of homodimers to estrogen response elements or association with transcription factors. ER alpha/ESR1 Protein, Human (P. pastoris, N-His) is the recombinant human-derived ER alpha/ESR1 protein, expressed by P. pastoris , with N-6*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-19822S1

Elacestrant-d4-1
Elacestrant-d₄-1 is the deuterium labeled Elacestrant (HY-19822). Elacestrant is an orally available and selective estrogen receptor degrader (SERD) with IC₅₀s of 48 and 870 nM for ERα and ERβ, respectively .

HY-B0723S

Ospemifene D4
Ospemifene-d₄ is a deuterium labeled Ospemifene. Ospemifene is a selective and orally active estrogen receptor modulator for the prevention of osteoporosis with IC50 values of 827 nM and 1633 nM for estrogen receptor α (ERα) and ERβ, respectively. Ospemifene has bone-sparing, antitumor, and cholesterol-lowering effects[1][2].

HY-19822S2

Elacestrant-d10
Elacestrant-d₁₀ is the deuterium labeled of Elacestrant (HY-19822). Elacestrant is an orally available and selective estrogen receptor degrader (SERD) with IC₅₀s of 48 and 870 nM for ERα and ERβ, respectively. Elacestrant also inhibits growth of ER ⁺ breast cancer cell lines in vitro and in vivo .

HY-19822S

Elacestrant-d4
Elacestrant-d₄ (RAD1901-d₄) is deuterated labeled Elacestrant (HY-19822) Elacestrant (RAD1901) is an orally available and selective estrogen receptor degrader (SERD) with IC₅₀s of 48 and 870 nM for ERα and ERβ, respectively. Elacestrant also can inhibit growth of ER ⁺ breast cancer cell lines in vitro and in vivo.

HY-19822S3

Elacestrant-d6
Elacestrant-d₆ (RAD1901-d₆) is deuterated labeled Elacestrant (HY-19822) Elacestrant (RAD1901) is an orally available and selective estrogen receptor degrader (SERD) with IC₅₀s of 48 and 870 nM for ERα and ERβ, respectively. Elacestrant also can inhibit growth of ER ⁺ breast cancer cell lines in vitro and in vivo.

HY-A0031S

Bazedoxifene-d4

Bazedoxifene-d₄ is deuterium labeled Bazedoxifene. Bazedoxifene (TSE-424) is an oral, BBB-penetrant nonsteroidal selective estrogen receptor modulator (SERM), with IC50s of 23 nM and 99 nM for ERα and ERβ, respectively. Bazedoxifene can be used for the research of osteoporosis. Bazedoxifene also acts as an inhibitor of IL-6/GP130 protein-protein interactions and can be used for the research of pancreatic cancer[1][2].

HY-A0031S2

Bazedoxifene-d4 acetate

Bazedoxifene-d₄ (acetate) is the deuterium labeled Bazedoxifene[1]. Bazedoxifene (TSE-424) is an oral, BBB-penetrant nonsteroidal selective estrogen receptor modulator (SERM), with IC50s of 23 nM and 99 nM for ERα and ERβ, respectively. Bazedoxifene can be used for the research of osteoporosis. Bazedoxifene also acts as an inhibitor of IL-6/GP130 protein-protein interactions and can be used for the research of pancreatic cancer[2][3].

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80663

	Estrogen Receptor alpha Antibody ESR1; ERa; ERalpha; Estrogen receptor; Estradiol receptor; ER-alpha; Estrogen receptor 1; NR3A1; ER; ESR; ESRA; Estrogen receptor alpha	WB, IHC-F, IHC-P, ICC/IF, IP, ChIP	Human
	Estrogen Receptor alpha Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 66 kDa, targeting to Estrogen Receptor alpha. It can be used for WB,IHC-F,IHC-P,ICC/IF,IP,ChIP assays with tag free, in the background of Human.

HY-P80662

	Estrogen Receptor alpha Antibody (YA768) ESR1; ERa; ERalpha; Estrogen receptor; Estradiol receptor; ER-alpha; Estrogen receptor 1; NR3A1; ER; ESR; ESRA; Estrogen receptor alpha	WB	Human, Mouse, Rat
	Estrogen Receptor alpha Antibody (YA768) is a non-conjugated and Mouse origined monoclonal antibody about 66 kDa, targeting to Estrogen Receptor alpha (6F11). It can be used for WB assays with tag free, in the background of Transfected.